First world launch for Evenity
The world-first launch has taken place of the humanized anti-sclerostin monoclonal antibody Evenity (romosozumab ) in Japan for the treatment of osteoporosis in patients with a high risk of fracture, according to Amgen Astellas BioPharma.
The joint venture of US biotech Amgen (Nasdaq: AMGN) and Japan’s Astellas (TYO: 4503) is developing Evenity in cooperation with Belgian drugmaker UCB (Euronext: UCB). News of the launch saw Astellas’ shares edge up 1.12% to 1,762 yen today.
Amgen Astellas and Astellas will co-promote Evenity. Based on an agreement between UCB and Amgen, UCB Japan is responsible for a disease state approach to raise awareness, understanding and treatment rates for patients with osteoporosis in Japan. UCB Japan will not be involved in product promotion for Evenity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze